Standard BioTools Inc (NASDAQ:LAB) shares, rose in value on Wednesday, June 18, with the stock price up by 6.86% to the previous day’s close as strong demand from buyers drove the stock to $1.09.
Actively observing the price movement in the last trading, the stock closed the session at $1.02, falling within a range of $1.03 and $1.12. The value of beta (5-year monthly) was 1.505. Referring to stock’s 52-week performance, its high was $2.41, and the low was $0.92. On the whole, LAB has fluctuated by 3.81% over the past month.
With the market capitalization of Standard BioTools Inc currently standing at about $414.01 million, investors are eagerly awaiting this quarter’s results, scheduled for on 2025-May-06.
Technical indicators serve as essential tools for traders, offering insights into market sentiment and potential price movements. We see that LAB’s technical picture suggests that short-term indicators denote the stock is a 50% Sell on average. However, medium-term indicators have put the stock in the category of 100% Sell while long-term indicators on average have been pointing out that it is a 100% Sell.
The stock’s technical analysis shows that the price of LAB currently trading nearly 4.26% and -0.56% away from the simple moving averages for 20 and 50 days respectively. The Relative Strength Index (RSI, 14) currently indicates a reading of 52.02, while the 7-day volatility ratio is showing 6.30% which for the 30-day chart, stands at 5.32%. Furthermore, Standard BioTools Inc (LAB)’s beta value is 1.50, and its average true range (ATR) is 0.08.
A comparison of Standard BioTools Inc (LAB) with its peers suggests the former has fared considerably weaker in the market. LAB showed an intraday change of 6.86% in last session, and over the past year, it shrunk by -49.30%%.
Data on historical trading for Standard BioTools Inc (NASDAQ:LAB) indicates that the trading volumes over the past 10 days have averaged 0.94 and over the past 3 months, they’ve averaged 1.27 million. According to company’s latest data on outstanding shares, there are 379.09 million shares outstanding.
Nearly 3.66% of Standard BioTools Inc’s shares belong to company insiders and institutional investors own 72.28% of the company’s shares. The data on short interest also indicates that stock shorts accounted for 17.04 million shares as on 2025-05-30, resulting in a short ratio of 10.91. According to the data, the short interest in Standard BioTools Inc (LAB) stood at 765.00 of shares outstanding as of 2025-05-30; the number of short shares registered in 2025-04-30 reached 18.44 million. The stock has fallen by -37.71% since the beginning of the year, thereby showing the potential of a further growth. This could raise investors’ confidence to be optimistic about the LAB stock heading into the next quarter.
